Type 1 Diabetes Efficacy Studies
In Vivo Pharmacology Services at JAX performs contract efficacy studies using NOD/ShiLtJ (001976) mice to evaluate new Type 1 diabetes-related therapeutics
In Vivo Pharmacology Services at JAX performs contract efficacy studies using NOD/ShiLtJ (001976) mice to evaluate new Type 1 diabetes-related therapeutics
Autoimmune destruction of pancreatic beta cells causes type 1 diabetes with a female bias
A mutation destabilizing insulin causes rapid insulin-dependent diabetes with a male bias
Chemical depletion of pancreatic beta cells mimics the end stages of type 1 diabetes in C57BL/6J, NOD scid, NSG™ and other strains.
We use cookies to personalize our website and to analyze web traffic to improve the user experience. You may decline these cookies although certain areas of the site may not function without them. Please refer to our privacy policy for more information.
Allow essential cookies
Required for basic site operations.
Allow analytics cookies
Used to analyze web traffic to improve the user experience.
Allow marketing cookies
Used to deliver personalized information and tailor communications.